Testing Gaps as FDA Moves Toward MRD-Based Myeloma Approvals: Journal Article

Share

A new scientific review highlights unresolved assay-validation challenges facing multiple myeloma drug developers as FDA moves toward allowing measurable residual disease (MRD) negativity to serve as a primary endpoint supporting accelerated approval.

The review, published 10/23 in the International Journal of Molecular Sciences, compares next-generation flow cytometry, next-generation sequencing and blood-based mass spectrometry for detecting residual cancer cells. It concludes that while emerging blood-based methods offer less invasive monitoring, they have not been sufficiently validated to replace bone marrow testing in clinical trials.

The findings are relevant to FDA's January draft guidance (see earlier story), which proposes using MRD negativity and complete response as endpoints supporting accelerated approval of multiple myeloma drugs and biologics. The agency's proposed MRD endpoint relies on bone marrow assessments using flow cytometry or sequencing.

The authors found that blood-based mass spectrometry could complement established methods but cautioned that combining blood- and marrow-based testing requires prospective validation before broader clinical adoption.

Read more